Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity

International Journal of Geriatric Psychiatry - Tập 25 Số 4 - Trang 403-410 - 2010
Kajsa Sämgård1, Henrik Zetterberg2, Kaj Blennow2, Oskar Hansson1, Lennart Minthon1, Elisabet Londos1
1Clinical Memory Research Unit, Department of Clinical Sciences Malmo, Lund University, Lund, Sweden
2Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden

Tóm tắt

AbstractObjectivesThe aim of this longitudinal study was to test the hypothesis that CSF biomarkers in AD patients also may be forward‐looking measures that are associated not only with the degree and profile of cognitive impairment but also with changes in cognition over time.MethodsHere, we assessed the association of CSF Aβ42, T‐tau and P‐tau with neuropsychological scores of disease severity, as well as the rate of disease progression, in 142 patients with Alzheimer's disease. All patients were part of a 3‐year prospective longitudinal treatment study.ResultsA more rapid progress in MMSE score reduction was seen in AD patients with T‐tau levels higher than the upper quartile (800 ng/L) compared with Alzheimer's disease patients with lower T‐tau levels (p = 0.008). We also found that individuals with T‐tau > 800 ng/L performed worse in total scores and especially in memory and orientation when assessed with MMSE and ADAS cog than patients with T‐tau <800 ng/L. Similar results were obtained for P‐tau. No associations were seen between Aβ42 and cognitive scores or disease progression.DiscussionThese findings support the hypothesis that increased levels of T‐tau reflect the intensity of the disease and are associated with a more rapid disease progress. Copyright © 2009 John Wiley & Sons, Ltd.

Từ khóa


Tài liệu tham khảo

10.1007/BF00688184

American Psychiatry Association, 1994, Diagnostic and Statistical Manual of Mental Disorders (DSMIV)

10.1136/jnnp.64.3.298

10.1212/WNL.42.3.631

10.1001/archneur.60.6.813

10.1016/S0140-6736(06)69113-7

10.1016/j.neulet.2007.03.064

10.1007/BF00308809

10.1093/brain/awl178

10.1002/ana.20730

10.1016/S0140-6736(05)67889-0

10.1016/0022-3956(75)90026-6

10.1602/neurorx.1.2.181

10.1073/pnas.83.13.4913

10.1016/S1474-4422(06)70355-6

10.1212/01.WNL.0000156914.16988.56

10.3233/JAD-2000-23-402

10.1016/S0304-3940(00)01697-9

10.1016/S0140-6736(86)92134-3

10.1002/ana.20639

10.1002/ana.21223

10.1002/ana.410440108

10.1212/WNL.34.7.939

10.1006/abbi.1993.1112

Mohs RC, 1983, The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy, Psychopharmacol Bull, 19, 448

10.1017/S135561770808079X

10.1021/pr050475v

10.1038/sj.mp.4001220

10.1111/j.1471-4159.1993.tb09834.x

10.1034/j.1600-0404.106.s178.2.x

10.1016/j.jns.2005.05.016

10.1016/j.jns.2006.09.014

10.1159/000105017

10.1212/01.WNL.0000046581.81650.D0

10.1016/S0006-3223(99)00143-2

10.1016/S0304-3940(01)01556-7

10.1056/NEJMoa022066

10.1016/S0304-3940(02)01483-0

10.1159/000090631

10.1159/000098052

10.1002/gps.2195

10.1016/S0072-9752(07)01224-9

10.1016/j.neulet.2003.08.011

10.1001/archneur.63.9.1277

10.3233/JAD-2007-12307

Thông tin
Thông tin xuất bản

International Journal of Geriatric Psychiatry

Tập 25 Số 4

403-410

Thông tin tác giả